Milton C. Ault III - 26 Aug 2026 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Reporting relationship: Director
Issuer ticker: ALZN
Reported as of: 26 Aug 2026
Net transaction value: -$3,116
SEC form: 4
Accepted by SEC: 31 Aug 2026, 06:05:03 UTC
Prior SEC filing: 26 Aug 2026
Next SEC filing: 31 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Milton C. Ault, III

Key filing fact

Milton C. Ault III filed Form 4 for Alzamend Neuro, Inc. (ALZN) on 31 Aug 2026.

Key facts

This page summarizes Milton C. Ault III's Form 4 filing for Alzamend Neuro, Inc. (ALZN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Aug 2026, 06:05.

Change

Previous filing in this sequence was filed on 26 Aug 2026.
Current net transaction value: -$3,116.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001212502 Primary reporting owner

AULT MILTON C III

Relationship: Director
Address: 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 190, LAS VEGAS
Signature: /s/ Milton C. Ault, III
Signature date: 31 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALZN transaction

Common Stock

Sale

Transaction value: $3,116
Shares: -2,000
Change %: -100%
Price: $1.56
Shares after: 0
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ALZN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 116,648
Date: 26 Aug 2026
Ownership: By Ault Lending, LLC
Footnotes: F3

ALZN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,068
Date: 26 Aug 2026
Ownership: By Ault Life Sciences, Inc.
Footnotes: F4

ALZN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 61
Date: 26 Aug 2026
Ownership: By Ault Life Sciences Fund, LLC
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The sale of these shares is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.

Footnote F2

The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $1.5581. The range of sale prices on the transaction date was $1.55 to $1.5619 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

Footnote F3

Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

Footnote F4

Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

Footnote F5

Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

SEC remarks

Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer.